Table 2

Final proportional hazards modela for breast cancer specific survival at 10 years follow-up

VariableUnivariateMultivariate
RRb (95% CI)PRR (95% CI)P
A. All patients (n = 241)
Tumor size
 <2 cm1.001.00
 ≥2 cm3.09 (1.75–5.46)0.00012.08 (1.14–3.80)0.02
Lymph nodes
 Negative1.001.00
 Positive2.78 (1.60–4.83)0.00032.58 (1.45–4.56)0.001
p53
 Negative1.001.00
 Positive2.57 (1.54–4.28)0.00031.70 (0.99–2.90)0.05
p27Kip1
 Negative1.001.00
 Positive0.43 (0.23–0.78)0.0060.51 (0.28–0.95)0.03
Cyclin E
 Negative1.001.00
 Positive2.63 (1.58–4.38)0.00021.99 (1.16–3.41)0.01
GMP
 None1.001.00
 >02.68 (1.55–4.62)0.00042.34 (1.31–4.21)0.004
B. Node-negative disease (n = 120)
Tumor size
 <2 cm1.001.00
 ≥2 cm1.68 (0.68–4.13)0.260.99 (0.39–2.55)0.99
p53
 Negative1.001.00
 Positive2.48 (0.98–6.30)0.061.20 (0.44–3.24)0.73
p27Kip1
 Negative1.001.00
 Positive0.21 (0.06–0.72)0.010.24 (0.07–0.85)0.03
Cyclin E
 Negative1.001.00
 Positive5.13 (2.01–13.0)0.00063.53 (1.34–9.28)0.01
GMP
 None1.001.00
 >01.85 (0.67–5.14)0.241.78 (0.60–5.25)0.30
C. Node-positive disease (n = 100)
Tumor size
 <2 cm1.001.00
 ≥2 cm3.45 (1.43–8.32)0.0063.95 (1.47–10.6)0.007
p53
 Negative1.001.00
 Positive2.20 (1.15–4.22)0.021.99 (0.99–4.00)0.05
p27Kip1
 Negative1.001.00
 Positive0.74 (0.36–1.52)0.410.87 (0.41–1.83)0.70
Cyclin E
 Negative1.001.00
 Positive2.03 (1.02–4.03)0.041.24 (0.59–2.61)0.58
GMP
 None1.001.00
 >03.16 (1.56–6.44)0.0023.16 (1.44–6.95)0.004
  • a Adjusted for all missing variables. Final model excludes cases for which adjustment was not possible (n = 6); cases with unknown nodal status are not included.

  • b RR, relative risk; CI, confidence interval; GMP, glomeruloid microvascular proliferation.